Clinical investigation of plasma-derived antithrombin products

  • Email
  • Help
Current effective version

Adopted guideline

Reference numberCPMP/BPWG/2220/99
Effective from01/07/2002
Keywords Congenital antithombin deficiency, acquired antithombin deficiency
DescriptionThis document summarises the clinical trials required for authorisation of new and modified human plasma derived antithrombin products.

Related content

How helpful is this page?

Average rating:

 Based on 20 ratings

Add your rating:

See all ratings
4 ratings
4 ratings
4 ratings
4 ratings
4 ratings

Tell us more